Results from an international phase 3 trial of Johnson & Johnson’s single-dose COVID-19 vaccine show it is overall 66% effective in preventing moderate to severe symptoms of COVID-19. The vaccine was 85% effective in preventing severe COVID-19 disease and 100% effective in preventing COVID-19-related hospitalizations and deaths. The vaccine has been a long-hoped for game-changer in the global fight against the pandemic because it requires only one dose, can be manufactured in billions of doses, and requires only standard refrigeration.

 

microgen

Read more CIDRAP…